Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

89.50USD
18 Jan 2019
Change (% chg)

$2.30 (+2.64%)
Prev Close
$87.20
Open
$87.90
Day's High
$89.53
Day's Low
$86.95
Volume
2,068,556
Avg. Vol
1,812,599
52-wk High
$125.84
52-wk Low
$77.50

Select another date:

Fri, Jan 18 2019

Photo

AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

UPDATE 1-AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

Jan 18 AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

AbbVie's cancer drug fails to meet main goal in late-stage study

Jan 18 AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Abbvie to record $4 billion impairment charges on Stemcentrx assets

Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

Abbvie to record $4 bln impairment charges on Stemcentrx assets

Jan 4 Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.

REFILE-Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Dec 17 Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.

AbbVie halts late-stage trial for lung cancer drug Rova-T

AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

UPDATE 1-AbbVie halts late-stage trial for lung cancer drug Rova-T

Dec 5 AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

AbbVie halts late-stage trial for lung cancer drug Rova-T

Dec 5 AbbVie said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

Select another date: